Coronaridine |
Catalog No.GC64816
One-Click Copy Product Info
|
Coronaridine is an inhibitor of TCF/β-catenin, with an IC50 value of 5.8μM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 467-77-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Coronaridine is an inhibitor of TCF/β-catenin, with an IC50 value of 5.8μM[1]. Coronaridine has been widely used in neurological function studies and in development of congeners[2].
In vitro, Coronaridine showed potent cytotoxic activity in the laryngeal carcinoma cell line Hep-2, with an IC50 value of 54.47µg/mL) after 24h treatment[3]. Coronaridine treatment (10μg/ml; 24h) exhibited potent antileishmanial activity, suppressing promastigote and amastigote growth[4].
In vivo, Coronaridine treatment (72mg/kg; p.o.) for 25 minutes produced a sedative effect and reduced spontaneous activity in Male CD-1 albino mice [5].
References:
[1] Ohishi K, Toume K, Arai M A, et al. Coronaridine, an iboga type alkaloid from Tabernaemontana divaricata, inhibits the Wnt signaling pathway by decreasing β-catenin mRNA expression[J]. Bioorganic & medicinal chemistry letters, 2015, 25(18): 3937-3940.
[2] Arias H R, Tae H S, Micheli L, et al. Coronaridine congeners decrease neuropathic pain in mice and inhibit α9α10 nicotinic acetylcholine receptors and CaV2. 2 channels[J]. Neuropharmacology, 2020, 175: 108194.
[3] Rizo W F, Ferreira L E, Colnaghi V, et al. Cytotoxicity and genotoxicity of coronaridine from Tabernaemontana catharinensis A. DC in a human laryngeal epithelial carcinoma cell line (Hep-2)[J]. Genetics and molecular biology, 2013, 36: 105-110.
[4] Delorenzi J C, Attias M, Gattass C R, et al. Antileishmanial activity of an indole alkaloid from Peschiera australis[J]. Antimicrobial Agents and chemotherapy, 2001, 45(5): 1349-1354.
[5] Arias H R, Tae H S, Micheli L, et al. Coronaridine congeners decrease neuropathic pain in mice and inhibit α9α10 nicotinic acetylcholine receptors and CaV2. 2 channels[J]. Neuropharmacology, 2020, 175: 108194.
| Cell experiment [1]: | |
Cell lines | Hep-2 cells |
Preparation Method | Hep-2 cells (2×104 cells/mL) were incubated with 15.62, 31.25, 62.5, and 125µg/mL Coronaridine, respectively, for 6 hours at 37°C in a 5% CO2 atmosphere. Minor modifications were made to the alkaline comet assay. Three hundred cells were randomly selected from three replicate slides, for a total of=900 cells, and each Coronaridine concentration was analyzed. The cells were scored for damage and divided into five categories to calculate the DNA damage index. Doxorubicin 0.2μg/mL was used as a positive control, and 1% dimethyl sulfoxide was used as a solvent control. |
Reaction Conditions | 15.62, 31.25, 62.5, and 125µg/mL; 6h |
Applications | Coronaridine treatment increased DNA damage in Hep-2 cell line in a concentration-dependent manner. |
| Animal experiment [2]: | |
Animal models | Male CD-1 albino mice |
Preparation Method | Male CD-1 albino mice weighing approximately 22 to 25g at the beginning of the experiment were used in all experiments. Ten mice were housed in each cage (26 ×41cm). Animals were fed a standard laboratory diet and tap water AD libitum and maintained at 23±1°C on a 12-h day-night cycle with light at 7 am. Neuropathic pain was produced in mice (n=10/group) intermittently by intraperitoneal (i.p.) injection of 2.4mg/kg oxaliplatin (dissolved in 5% glucose solution) on days 1-3, 6-10, and 13-14. On day 15, a coronary contrast agent (Coronaridine) that induces antineuropathic pain was administered (p.o.) at the highest dose (72mg/kg), and a hole-plate test was performed 25 minutes later. The device consisted of a 40cm square plane with 16 flush cylindrical holes (3cm in diameter) distributed in a 4×4 equispaced grid. Each mouse was placed in the center of the plate and allowed to move freely for 5min at a time. Two light beams passed from the midpoint of the plane to the midpoint on opposite sides, thus dividing the plane into four equal quadrants, automatically signaling the movement of the animal across the plate surface for a total time of 5min (i.e., spontaneous activity). Miniature photocells were present in each of the 16 wells, and the mice were recorded for a total of 5min of hole exploration time. Higher or lower exploratory activity compared with control animals indicates anxiolytic or anxiogenic activity of the drug, respectively. |
Dosage form | 72mg/kg for 25min; p.o. |
Applications | Coronaridine treatment decreased locomotor activity and reduced spontaneous mobility in mice. |
References: | |
| Cas No. | 467-77-6 | SDF | |
| Formula | C21H26N2O2 | M.Wt | 338.44 |
| Solubility | Storage | 4°C, protect from light | |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.9547 mL | 14.7737 mL | 29.5473 mL |
| 5 mM | 590.9 μL | 2.9547 mL | 5.9095 mL |
| 10 mM | 295.5 μL | 1.4774 mL | 2.9547 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)